Proprietary blend of cranberry powder, D-mannose, and vitamin D3 reduces risk of UTI relapse in recent study
A recent study showed that a supplement product marketed by Pharmalinea as >Your< UTI Free Sachets may help reduce the frequency of relapse of urinary tract infections and improve quality of life when paired with an antibiotic treatment.
Photo © AdobeStock.com/ martina87
A recent study1 showed that a supplement product marketed by Pharmalinea as >Your< UTI Free Sachets may help reduce the frequency of relapse of urinary tract infections and improve quality of life when paired with an antibiotic treatment. The product contains 2000 mg of D-mannose, 500 mg of Qcran, a proprietary whole-fruit cranberry powder, and 40 IU of vitamin D3. In the study, 98 female subjects between the ages of 18 and 80 with active acute cystisis were randomized into parallel groups to receive either the antibiotic treatment alone (control) or the antibiotic in combination with >Your< UTI Free Sachets.
Results showed that after 12 weeks, the control group had a significantly higher rate of relapse (77.6%), compared to the group receiving the combined treatment (19.2%). There was also a significant improvement of quality of life in subjects taking the combined treatment (20%).
“Recurrent infections are not only an immediate issue for the consumer but can have larger implications. Repeating UTIs and subsequent prescriptions of antibiotics can lead to antibiotic resistance – one of the most pressing global issues. The WHO’s ‘Global action plan on antimicrobial resistance’ includes two strategic goals: to reduce the incidence of infection and to optimize antimicrobial medicine use. With our product and the presented clinical trial, we aimed to support both those goals,“ stated Maja Orešnik, science and research director at PharmaLinea, in a press release.
“Already a commercial success, the product has secured the number one spot in two European markets and has been launched by brand owners in multiple markets across Europe, Asia, LATAM, and the Middle East. The new clinical data is bound to only increase the opportunity, “ said Jernej Klopčič, PharmaLinea's business development director. The B2C brand name of the product is called Uronext, marketed by Petrovax Pharm.
“Our UTI products are a unique combination of our own proprietary whole-fruit cranberry ingredient Qcran, a clinically relevant dose of D-mannose, and microencapsulated vitamin D3, packed in a single sachet. Qcran is one of the few if not only cranberry ingredient that is 100% whole fruit, without any sort of extraction taking place. This is achieved through a unique cold fusion production process,” explained PharmaLinea's marketing director Matevž Ambrožič, in a press release. “The resulting product retains all the beneficial properties of cranberries, including a very high fiber content, higher than any other cranberry ingredient we’ve tested. This results in the active ingredient PAC being protected, released into the bloodstream in a sustained manner, and ultimately having higher efficacy. Clinical trials are relatively rare for finished products in supplements and even more so for private label products. The investment in extensive scientific support of the product was made to empower both women and doctors with an important tool for prevention and care.”
Reference
- Khodyreva, L.A.; Bernikov, A.N.; Kupriyanov, Y.A.; Arefieva, O.A.; Orešnik, M.; and Pushkar, D.Y. Prospective study on the efficacy and safety of Uronext® in parallel groups in women with acute cystitis. EC Gynaecology. 2024, 13 (2).
